HB4167 amends Michigan’s sentencing guidelines table in the Code of Criminal Procedure to add and integrate offenses related to xylazine, a veterinary sedative increasingly associated with illicit drug use. The bill assigns offense classes and statutory maximum penalties for xylazine-related conduct, including delivery or manufacture of xylazine for illicit use, possession of xylazine for illicit use, and fraudulently obtaining xylazine for illicit use. It also includes a related offense for selling or offering objects used for the illicit use of xylazine.
The bill updates the list of covered felonies in MCL 777.13m so that these xylazine offenses are treated within Michigan’s sentencing guidelines framework alongside existing controlled-substance crimes. It also makes a technical cross-reference to House Bill 4166, providing that HB4167 will not take effect unless that companion bill is enacted. In practical terms, the bill would affect sentencing exposure for defendants convicted of the newly listed xylazine-related offenses and would guide courts in scoring those offenses under the state’s guidelines.
Impact
HB4167 would amend MCL 777.13m, the statute that identifies which controlled-substance felonies are subject to Michigan’s sentencing guidelines and what offense class and statutory maximum apply. The bill adds xylazine-related offenses and related paraphernalia-type conduct to that list, thereby affecting sentencing calculations for prosecutors, defense counsel, and courts handling drug cases. Because the bill is tied to HB4166 by a conditional enactment clause, its legal effect depends on passage of the companion legislation as well.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of legislative debate or roll-call sentiment in the available record. Based on the bill text and caption, the measure appears to be a targeted, technical sentencing update aimed at addressing emerging illicit-drug activity involving xylazine. The overall tone of the bill is regulatory and punitive rather than controversial on its face, but the absence of discussion makes it impossible to assess broader support or opposition from the record provided.
Contention
The main policy issue likely to draw attention is whether xylazine should be treated like other controlled-substance offenses for sentencing purposes, including how severe the penalties should be for possession, delivery, and fraud-related conduct. Another possible point of contention is the bill’s inclusion of objects used for the illicit use of xylazine, which could raise questions about breadth and enforcement. The conditional tie to HB4166 is also notable, because the bill cannot take effect independently; that linkage may matter to lawmakers concerned about package legislation or the sequencing of related criminal-law changes.